110 related articles for article (PubMed ID: 2573371)
41. Cardiovascular and renal effects of the beta-blocker SE2395 in conscious normotensive dogs.
Walker BR; Erickson AL; Prost JF; Rochat C; Burke TJ
J Cardiovasc Pharmacol; 1985; 7(6):1193-7. PubMed ID: 2418310
[TBL] [Abstract][Full Text] [Related]
42. Study of prejunctional beta-adrenoceptors in kidneys of normotensive and hypertensive rats using the new beta-adrenoceptor blocking drug tertatolol.
Verbeuren TJ; Herman AG
Am J Nephrol; 1986; 6 Suppl 2():30-5. PubMed ID: 2879470
[TBL] [Abstract][Full Text] [Related]
43. Vasodilator effect of tertatolol in isolated perfused rat kidneys: involvement of endothelial 5-HT1A receptors.
Verbeuren TJ
Cardiology; 1993; 83 Suppl 1():5-9. PubMed ID: 7903215
[TBL] [Abstract][Full Text] [Related]
44. Tertatolol in chronic renal failure. A pharmacokinetic study.
Rainfray M; Rocher I; Mignon F; Meyrier A
Am J Hypertens; 1989 Nov; 2(11 Pt 2):266S-277S. PubMed ID: 2573374
[TBL] [Abstract][Full Text] [Related]
45. Effects of levosimendan on glomerular filtration rate, renal blood flow, and renal oxygenation after cardiac surgery with cardiopulmonary bypass: a randomized placebo-controlled study.
Bragadottir G; Redfors B; Ricksten SE
Crit Care Med; 2013 Oct; 41(10):2328-35. PubMed ID: 23921271
[TBL] [Abstract][Full Text] [Related]
46. Comparative renal and cardiac effects of tertatolol and enalapril in essential hypertension.
Ribstein J; Du Cailar G; Brouard R; Mimran A
Cardiology; 1993; 83 Suppl 1():57-63. PubMed ID: 7903217
[TBL] [Abstract][Full Text] [Related]
47. Comparison of the antihypertensive and renal effects of tertatolol and nadolol in hypertensive patients with mild renal impairment.
Fallo F; Gregianin M; Bui F; Macrì C; Folino P; Mantero F
Eur J Clin Pharmacol; 1991; 40(3):309-11. PubMed ID: 1676368
[TBL] [Abstract][Full Text] [Related]
48. Tertatolol: a beta-blocker with unique effects on human glomerular cell function.
Shultz P; Raij L
Cardiology; 1993; 83 Suppl 1():51-6. PubMed ID: 7903216
[TBL] [Abstract][Full Text] [Related]
49. Overview of clinical safety and efficacy of tertatolol.
Vivet P
Cardiology; 1993; 83 Suppl 1():41-50. PubMed ID: 7903214
[TBL] [Abstract][Full Text] [Related]
50. Cardiovascular response to adrenergic stimulation during treatment with tertatolol. A new non-cardioselective beta-blocking agent in primary hypertensive patients.
Fasano ML; Gaeta I; De Simone G; Iannuzzi R; Ferrara LA
Jpn Heart J; 1991 Jul; 32(4):435-44. PubMed ID: 1683411
[TBL] [Abstract][Full Text] [Related]
51. Effect of carvedilol on ambulatory blood pressure, renal hemodynamics, and cardiac function in essential hypertension.
Dupont AG; Van der Niepen P; Taeymans Y; Ingels M; Piepsz A; Bossuyt AM; Block P; Six RO; Jonckheer MH; Vanhaelst L
J Cardiovasc Pharmacol; 1987; 10 Suppl 11():S130-6. PubMed ID: 2454359
[TBL] [Abstract][Full Text] [Related]
52. Short tertatolol treatment does not impair the hormone and metabolic responses to exercise and hypoglycemia in diabetics.
Lantz B; Paillard F; Nunez E; Assan R
Horm Metab Res; 1989 Oct; 21(10):561-5. PubMed ID: 2572524
[TBL] [Abstract][Full Text] [Related]
53. Effects of tertatolol on post- and prejunctional beta adrenoceptors.
Verbeuren TJ; Laekeman G; Majchrowicz BB; Jordaens FH; Zonnekeyn LL; Herman AG
J Pharmacol Exp Ther; 1985 Jun; 233(3):801-9. PubMed ID: 2861280
[TBL] [Abstract][Full Text] [Related]
54. Beta-adrenergic receptor changes during tertatolol treatment in healthy volunteers: relevance for beta-blocking therapy.
De Blasi A; Lipartiti M; Garattini S
Am J Nephrol; 1986; 6 Suppl 2():69-73. PubMed ID: 2879475
[TBL] [Abstract][Full Text] [Related]
55. Glucagon-like peptide-1 does not have acute effects on central or renal hemodynamics in patients with type 2 diabetes without nephropathy.
Asmar A; Simonsen L; Asmar M; Madsbad S; Holst JJ; Frandsen E; Moro C; Sorensen CM; Jonassen T; Bülow J
Am J Physiol Endocrinol Metab; 2016 May; 310(9):E744-53. PubMed ID: 26956188
[TBL] [Abstract][Full Text] [Related]
56. Amlodipine reduces cyclosporin-induced hyperuricaemia in hypertensive renal transplant recipients.
Chanard J; Toupance O; Lavaud S; Hurault de Ligny B; Bernaud C; Moulin B
Nephrol Dial Transplant; 2003 Oct; 18(10):2147-53. PubMed ID: 13679494
[TBL] [Abstract][Full Text] [Related]
57. Preserving the autoregulation of renal hemodynamics.
Beaufils M
Cardiology; 1993; 83 Suppl 1():10-5. PubMed ID: 7903210
[TBL] [Abstract][Full Text] [Related]
58. Peripheral haemodynamic effects of inhibition of prostaglandin synthesis in congestive heart failure and interactions with captopril.
Townend JN; Doran J; Lote CJ; Davies MK
Br Heart J; 1995 May; 73(5):434-41. PubMed ID: 7786658
[TBL] [Abstract][Full Text] [Related]
59. European experience with artex: the Tertatolol International Multicentre Study (TIMS).
Laher MS
Cardiology; 1993; 83 Suppl 1():25-31. PubMed ID: 7903212
[TBL] [Abstract][Full Text] [Related]
60. Effects of nadolol on systemic and renal hemodynamics in patients with renoparenchymal hypertension and various degrees of renal function.
Valvo E; Gammaro L; Bedogna V; Cavaggioni M; Tonon M; Lupo A; Loschiavo C; Tessitore N; Oldrizzi L; Rugiu G
Int J Clin Pharmacol Ther Toxicol; 1986 Apr; 24(4):202-6. PubMed ID: 3710633
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
